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OBJECTIVE — Nonalcoholic fatty liver disease is highly prevalent in obese and type 2 dia-
betic individuals and is strongly associated with dyslipidemia and inﬂammation. Weight loss
and/or pharmacotherapy are commonly used to correct these abnormalities.
RESEARCH DESIGN AND METHODS — We performed a 16-week intervention trial
of a hypocaloric, low-fat diet plus 10 mg/day ezetimibe (n  15) versus a hypocaloric, low-fat
diet alone (n  10) on intrahepatic triglyceride (IHTG) content, plasma high sensitivity–C-
reactive protein (hs-CRP), adipocytokines, and fetuin-A concentrations and apolipoprotein
(apo)B-100 kinetics in obese subjects. ApoB-100 metabolism was assessed using stable isotope
tracer kinetics and compartmental modeling; liver and abdominal fat contents were determined
by magnetic resonance techniques.
RESULTS — Both weight loss and ezetimibe plus weight loss signiﬁcantly (all P  0.05)
reduced body weight, visceral and subcutaneous adipose tissues, insulin resistance and plasma
triglycerides, VLDL–apoB-100, apoC-III, fetuin-A, and retinol-binding protein-4 and increased
plasma adiponectin concentrations. Compared with weight loss alone, ezetimibe plus weight
loss signiﬁcantly (all P  0.05) decreased IHTG content (18%), plasma hs-CRP (53%),
interleukin-6 (24%), LDL cholesterol (18%), campesterol (59%), and apoB-100 (14%)
levels, with a signiﬁcant increase in plasma lathosterol concentrations (43%). The LDL–apoB-
100 concentration also signiﬁcantly fell with ezetimibe plus weight loss (12%), chieﬂy owing
to an increase in the corresponding fractional catabolic rate (29%). The VLDL–apoB-100
secretion rate fell with both interventions, with no signiﬁcant independent effect of ezetimibe.
CONCLUSIONS — Addition of ezetimibe to a moderate weight loss diet in obese subjects
can signiﬁcantly improve hepatic steatosis, inﬂammation, and LDL–apoB-100 metabolism.
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T
he prevalence of nonalcoholic fatty
liverdisease(NAFLD)inthegeneral
population is up to 30% but is
higher in those with type 2 diabetes and
obesity (1,2). NAFLD is also strongly as-
sociated with dyslipidemia and inﬂam-
mation, which may account for increased
risk of cardiovascular disease (CVD) in
these subjects (2). Reducing intrahepatic
triglyceride (IHTG) content may help to
reduce risk of hepatic and cardiovascular
complications.
Visceral fat accumulation in obese
subjects increases the portal delivery of
freefattyacidstotheliver,whichnotonly
stimulates hepatic gluconeogenesis and
triglyceride synthesis but also impairs he-
patic extraction of insulin (3). Insulin re-
sistance increases IHTG and hepatic
secretionofapolipoprotein(apo)Bbysev-
eral mechanisms (4,5). These include in-
creased fatty acid ﬂux to the liver,
increased de novo lipogenesis related to
increased expression of sterol regulatory
element–binding protein-1c (SREBP-lc),
decreased expression of peroxisome pro-
liferator–activated receptors, increased
triglyceride availability owing to in-
creased expression of microsomal triglyc-
eride transfer protein, and resistance to a
direct inhibitory effect of insulin on apoB
secretion. Insulin resistance also de-
creases the catabolism of LDL by down-
regulating LDL receptor expression and
activity (6).
Weight reduction through dietary in-
tervention is the cornerstone of manage-
ment of obesity and/or NAFLD (1,7). We
have reported previously that weight re-
duction (10% body weight) with a low-
fat diet effectively decreases plasma
triglycerides and apoB-100 (8). However,
such intensive weight loss is difﬁcult to
achieve and maintain. Moderate weight
loss of 3–7% is therefore a more realistic
goal to be implemented in clinical prac-
tice. Whether this level of weight loss
could lead to adequate improvement in
fattyliveranditsassociatedmetabolicdis-
orders remains unclear.
Ezetimibe is a potent cholesterol ab-
sorption inhibitor that has been shown to
reduce cholesterol absorption and LDL
cholesterol concentrations (9,10).
Whereas ezetimibe treatment has been
shown to increase LDL–apoB-100 catab-
olism (11,12), its effect on VLDL–apoB-
100 transport is less consistent, with
either no effect or an increased secretion
rateasreportedpreviously.Therefore,the
combination of ezetimibe and weight loss
could be an optimal approach in the clin-
ical setting to improve dyslipidemia by
harnessing the complementary mecha-
nism of action of these interventions.
Moreover, ezetimibe has recently been
shown to improve liver steatosis and ﬁ-
brosis in animal models of metabolic syn-
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IHTG content and the associated meta-
bolic factors needs to be demonstrated in
humans.
In the present study, we tested the
hypothesis that the addition of ezetimibe
to a weight loss diet improves hepatic ste-
atosis and apoB-100 metabolism in sub-
jects with obesity. We also wished to
exploretheeffectsofezetimibeinthisset-
ting on plasma high-sensitivity (hs) C-re-
active protein (CRP), fetuin-A, and
adipocytokine concentration.
RESEARCH DESIGN AND
METHODS— Twenty-ﬁve centrally
obese subjects who were consuming, ad
libitum, weight-maintaining diets were
recruited for the study. None of the sub-
jects had type 2 diabetes, the APOE2/E2
genotype, macroproteinuria, creatinine-
mia (120 mol/l), hypothyroidism, or
abnormal liver enzymes (alanine amino-
transferase [ALT] 3 times the upper
limit of normal, i.e., 120 units/l for men
and 90 units/l for women) or consumed
more than 20 g alcohol/day. None re-
ported a history of CVD or was taking
antihypertensive medications or other
agents known to affect lipid metabolism.
The study was approved by the Ethics
Committee of the Royal Perth Hospital,
and informed consent was obtained.
Clinical protocols
Thestudywasarandomized,single-blind
interventiontrial.Twenty-ﬁveeligiblepa-
tients entered a 4-week run-in diet-
stabilizing period, at the end of which
they were switched to a hypocaloric diet
for 16 weeks immediately followed by a
6-week weight stabilization period with
an isocaloric diet. During the 22-week di-
etary intervention period, these subjects
were also randomly assigned to 10 mg/day
ezetimibe (nine men and six women) or
matching placebo (six men and four
women). Body composition was esti-
mated using a Holtain Body Composition
Analyser (Holtain, Dyfed, U.K.) from
which total fat and fat-free mass (FFM)
were derived. Dietary intake was assessed
for energy and major nutrients using
DIET 4 nutrient calculation software
(Xyris Software, Highgate Hill, QL, Aus-
tralia). The clinical protocol for adminis-
tration of [d3]-leucine infusion and blood
sampling was described previously (14).
Liver and abdominal fat
measurements
Proton magnetic resonance imaging of
liver and abdominal fat was performed
during the week of isotope infusion stud-
ies. A single volume-stimulated echo ac-
quisition mode sequence was used. The
manufacturer’s magnetic resonance spec-
troscopy processing software was used to
obtain the liver fat–to–liver water signal
ratio, which was converted to liver fat
percentage.
Magnetic resonance imaging of eight
transaxial segments at intervertebral disc
levels from T11 to S1 was performed us-
ing a 1.0T Picker magnetic resonance
scanner (Picker International, Cleveland,
OH) and a T1-weighted fast spin echo se-
quencewithahighfat–to–watersignalra-
tio.Visceralandsubcutaneousabdominal
adipose tissue areas were measured at the
level of the L3 vertebra.
Measurement of isotopic
enrichments and calculation of
kinetic parameters
VLDL, intermediate-density lipoprotein
(IDL),andLDLwereisolatedfrom2mlof
plasma by sequential ultracentrifugation.
The isolation procedures and the multi-
compartmental model used to describe
apoB-100 leucine tracer-to-tracee ratios
were described previously (14). The frac-
tional catabolic rates (FCRs) of VLDL,
IDL, and LDL–apoB-100 were derived
fromthemodelparametersgivingthebest
ﬁt. The pool sizes of VLDL, IDL, and
LDL–apoB-100 were calculated as the
product of corresponding concentration
(milligram per liter) and plasma volume
(0.045 l/kg body weight). The secretion
ratewascalculatedbymultiplyingFCRby
poolsize(milligramsperkilogramofFFM
per day).
Biochemical analytes
Plasma lipid and glucose concentrations
were determined by enzymatic methods.
LDL cholesterol was calculated by the
Friedewald calculation. Plasma total
apoA-I, apoB-100, and hs-CRP concen-
trations were determined by immunon-
ephelometry (Dade Behring, Deerﬁeld,
IL). Plasma insulin was measured by a
chemiluminescent immunometric assay
(Diagnostic Products, Los Angeles, CA),
and insulin resistance was estimated by
the homeostasis model assessment
(HOMA)score.ApoB-100concentrations
in VLDL, IDL, and LDL fractions were
measured as described by Beghin et al.
(15). Plasma lathosterol and campesterol
concentrations were assayed using gas
chromatography–mass spectrometry.
Plasma retinol-binding protein-4 (RBP-
4), fetuin-A, adiponectin, interleukin-6
(IL-6), and tumor necrosis factor- con-
centrations were determined using an en-
zyme immunoassay (R&D Systems,
Minneapolis, MN).
Statistical analysis
All analyses were carried out using SPSS
15 (SPSS, Chicago, IL). Associations were
examined using the simple linear regres-
sion method. Paired t tests were used to
assess changes within both treatment
groups for all variables. Adjustment for
differences in baseline covariates and
changes in variables during the study
were performed by ANCOVA using gen-
eral linear models. Statistical signiﬁcance
was deﬁned at the 5% level.
RESULTS
Subject characteristics
The subjects were middle-aged (mean 
SD, 57  8 years), normotensive (blood
pressure13319/7510mmHg),cen-
trallyobese(waistcircumference1069
cm and BMI 33  4 kg/m
2), insulin resis-
tant (HOMA score 3.0  1.4), and mildly
dyslipidemic (total cholesterol 5.8  1.0
mmol/landtriglycerides1.80.7mmol/l).
Ofthesubjects,21hadNAFLDasdeﬁned
by IHTG content 5%.
Dietary compliance
The reductions in total dietary energy in
the weight loss and ezetimibe plus weight
loss groups (8,269  789 vs. 5,811 
437 KJ and 8,365  531 vs. 6,167  316
KJ,respectively)andfatintake(362vs.
27  1% and 38  1 vs. 30  1%, re-
spectively) were similar; increased carbo-
hydrate intake was also similar in both
groups (weight loss 40  2 vs. 49  1%
and ezetimibe plus weight loss 38  1 vs.
46  2%, respectively). All changes were
statistically signiﬁcant (P  0.01). There
was no change in reported physical activ-
ity levels during the study in either the
weight loss or ezetimibe plus weight loss
groups (data not shown).
Body weight, body composition, and
biochemical characteristics
The effects of weight loss and ezetimibe
plus weight loss on body weight, body
composition, and biochemical character-
istics are shown in Table 1. Despite the
preintervention, IHTG and visceral and
subcutaneous fat contents were numeri-
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the group differences were not signiﬁcant
(all P  0.05). Both treatments (weight
loss and ezetimibe plus weight loss) re-
sulted in signiﬁcant reductions in body
weight, BMI, waist circumference, total
fat mass, visceral and subcutaneous ab-
dominaladiposetissueareas,plasmacon-
centrations of triglycerides, and apoC-III
as well as insulin and HOMA score. How-
ever, the magnitude of these changes was
not signiﬁcantly different between treat-
ment groups (all P  0.05). With weight
loss,therewasalsoasigniﬁcantreduction
inplasmalathosterol(16%).IHTGcon-
tent decreased signiﬁcantly in both
weightlossandezetimibeplusweightloss
groups. The reduction in IHTG was sig-
niﬁcantly (P  0.05) greater in the
ezetimibe plus weight loss (46%) than
in the weight loss (28%) group (Fig. 1).
Compared with weight loss alone,
ezetimibe plus weight loss also signiﬁ-
cantly (P  0.05) reduced plasma con-
centrations of total cholesterol (11%),
LDL cholesterol (18%), apoB-100
(14%), and campesterol (59%) but
increased plasma lathosterol (43%).
Plasma concentrations of glucose, HDL
cholesterol, apoA-I, and ALT were not
altered with either treatment. Changes
in ALT concentrations and IHTG con-
tent in individual subjects before and
after intervention are shown in supple-
mentary Table A (available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1765/DC1).
Plasma hs-CRP, adipocytokine, and
fetuin-A concentrations
The effects of weight loss and ezetimibe
plus weight loss on plasma hs-CRP, adi-
pocytokine, and fetuin-A concentrations
are shown in Table 2. Compared with
weight loss, ezetimibe plus weight loss
signiﬁcantly (P  0.05) lowered plasma
hs-CRP (53%) and IL-6 (24%) con-
centrations. Both weight loss and
ezetimibe plus weight loss treatments re-
sulted in a signiﬁcant decrease in RBP-4
(11and9%,respectively)andplasma
fetuin-A (37 and 22%, respectively).
Theplasmaadiponectinconcentrationin-
creasedsigniﬁcantlyinbothgroups(13
and 24%, respectively). Ezetimibe plus
weight loss treatment was also associated
with a signiﬁcant decrease in plasma tu-
mor necrosis factor- concentration.
However, the relative changes were not
signiﬁcantly different between the weight
loss and ezetimibe plus weight loss
groups (all P  0.05). In univariate anal-
ysis, a reduction in plasma hs-CRP with
ezetimibe was not associated with a cor-
responding change in IHTG nor with the
plasmaIL-6concentration(r0.328and
0.089, respectively).
ApoB-100 kinetics
The effects of weight loss and ezetimibe
plus weight loss on apoB-100 in VLDL,
IDL, and LDL are shown in Table 3. Both
weightlossandezetimibeplusweightloss
resulted in signiﬁcant reductions in the
concentrations (13 and 19%, respec-
tively)andsecretionratesofVLDL–apoB-
100 (29 and 13%, respectively)
without signiﬁcant changes in VLDL–
apoB-100 FCR (3 and 8%, respec-
tively). The decreases in VLDL–apoB-100
concentrations and secretion rates were
not signiﬁcantly different between the
groups. Compared with weight loss
alone, ezetimibe plus weight loss signiﬁ-
cantly decreased the plasma concentra-
tion of LDL–apoB-100 (12%) owing to
a signiﬁcant increase in FCR (29%).
There was no signiﬁcant difference in the
production rate of LDL–apoB-100.
CONCLUSIONS — We provide new
information concerning the effect of in-
hibiting intestinal cholesterol absorption
with ezetimibe in addition to weight loss
alone on intrahepatic triglyceride con-
tent, markers of inﬂammation, and apoB-
100 metabolism in subjects with obesity.
Our results demonstrate that relative to
weight loss, ezetimibe further decreases
IHTG content and plasma hs-CRP and
IL-6 concentrations. Ezetimibe also sig-
niﬁcantly reduced the concentration of
plasma LDL–apoB-100 by increasing its
fractional catabolic rate. These changes
were demonstrated against the back-
ground of the favorable effects of weight
loss alone on VLDL–apoB-100 metabo-
lism, insulin sensitivity, and plasma con-
centrations of adipocytokines and fetuin-A.
This is the ﬁrst study to demonstrate
the combined effects of ezetimibe and
weight loss on apoB-100 kinetics and re-
lated metabolic indexes in obese subjects.
Fewkineticstudieshaveexaminedtheef-
fect of ezetimibe on apoB-100 metabo-
lism in humans. In two separate studies
by Tremblay et al. (11,12), ezetimibe
monotherapy or coadministration with
Table 1—Clinical and biochemical characteristics before and after intervention in the weight
loss and ezetimibe plus weight loss groups
Weight loss Ezetimibe plus weight loss
0 22 weeks 0 22 weeks
n 10 15
Body weight (kg) 100  69 4  5* 94  38 7  3*
BMI (kg/m
2) 33  13 1  1* 32  13 1  1*
Waist (cm) 107  49 8  4* 106  29 6  2*
Total fat mass (kg) 39  43 5  4* 37  33 2  3*
Fat-free mass (kg) 60  35 9  35 6  35 5  3
Visceral fat at L3 vertebra (cm
2) 278  38 228  36† 257  25 213  22*
Subcutaneous fat at L3 vertebra (cm
2) 358  43 316  36† 278  30 257  28†
Intrahepatic triglyceride content (%) 22  51 6  4* 18  31 0  2*‡
Alanine aminotransferase (U/l) 32  52 6  42 9  23 0  3
Cholesterol (mmol/l) 5.8  0.2 5.5  0.2 5.8  0.3 4.9  0.3*‡
Triglyceride (mmol/l) 1.7  0.3 1.3  0.2† 2.0  0.2 1.5  0.1*
Nonesteriﬁed fatty acids (mEq/l) 0.62  0.07 0.56  0.06 0.74  0.11 0.75  0.10
HDL cholesterol (mmol/l) 1.3  0.2 1.3  0.1 1.1  0.1 1.1  0.1
LDL cholesterol (mmol/l) 3.7  0.2 3.7  0.2 3.8  0.3 3.1  0.2*‡
Lathosterol (mol/l) 12  11 0  2* 12  11 5  2†
Campesterol (mol/l) 5.4  0.9 4.9  0.7 9.1  1.5 3.2  0.5*
ApoA-I (g/l) 1.5  0.1 1.5  0.1 1.4  0.1 1.4  0.1
ApoB-100 (g/l) 1.2  0.1 1.1  0.1 1.2  0.1 0.9  0.1*‡
ApoC-III (mg/l) 176  15 153  16* 186  12 160  13*
Glucose (mmol/l) 5.5  0.2 5.7  0.2 5.5  0.2 5.6  0.1
Insulin (mU/l) 12  21 0  2† 12  19  1†
HOMA score 3.1  0.5 2.6  0.4† 2.9  0.3 2.2  0.3†
Data are means  SEM. There was no signiﬁcant group difference in the variables at baseline. *P  0.01,
value signiﬁcantly different from baseline value. †P  0.05. ‡P 0.05, value signiﬁcantly different using
general linear modeling after adjustment for relative changes in the weight loss group.
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IDL,andLDL–apoB-100inmenwithpri-
mary hypercholesterolemia and mixed
hyperlipidemia. However, the effect of
ezetimibe on the VLDL–apoB-100 secre-
tion rate was not consistent. Ezetimibe
could increase the VLDL–apoB-100 se-
cretion rate by a mechanism involving a
compensatory increase in hepatic choles-
terol synthesis with ezetimibe. We con-
ﬁrm our previous report that weight loss
decreases VLDL–apoB-100 secretion in
obesity (8) but now report that ezetimibe
does not decrease this further. Although
we did not conﬁrm that weight loss alone
signiﬁcantly increased the FCR of LDL–
apoB-100, we now show that ezetimibe
did increase LDL–apoB-100 FCR in insu-
lin-resistant obese subjects.
It is likely that the combination of
central obesity and insulin resistance col-
lectively accounts for the dysregulation of
apoB-100 metabolism (3,4). Therefore,
weight loss with a low-fat diet could po-
tentially correct the abnormalities in
apoB-100 metabolism by an improve-
ment in insulin sensitivity and reductions
in abdominal adipose tissue. Consistent
with this hypothesis, we found that both
weightlossandezetimibeplusweightloss
interventions signiﬁcantly reduced the
plasma VLDL–apoB-100 concentration
and secretion rate, probably owing to a
concomitant reduction in visceral and
subcutaneous adipose tissues and an im-
provement in insulin resistance.
Low adiponectin and elevated RBP-4
andfetuin-Aconcentrationsareknownto
be closely related to obesity and insulin
resistance (16,17). Our ﬁndings demon-
strate that weight loss and ezetimibe plus
weight loss interventions increased
plasma adiponectin and decreased RPB-4
and fetuin-A concentrations, in agree-
ment with other reports on weight loss.
Given that none of these changes, includ-
ing the VLDL–apoB-100 concentration
and secretion rate, differed between the
weightlossandezetimibeplusweightloss
groups, it is conceivable that all of these
favorable changes are chieﬂy driven by
the effects of weight loss.
In contrast with our previous report
(8), weight loss did not increase the FCR
of LDL–apoB-100 in this study. Discrep-
ancies between the two studies might
have been due to different experimental
protocols. In particular, we only exam-
ined the effect of moderate weight loss
(3–7%) in this study compared with
10% weight loss in our previous study.
Despite this difference, we found that,
compared with weight loss alone, addi-
tionofezetimibetoweightlossresultedin
a signiﬁcant decrease in the plasma LDL–
apoB-100 concentration, chieﬂy by in-
creasing its catabolism. This result is
consistent with the mechanism of action
Figure1—Effectsofweightlossandezetimibeplusweightlossonintrahepatictriglyceridecontentinobesesubjects.Therewasnosigniﬁcantgroup
difference in preintervention intrahepatic triglyceride content (P  0.05). *P  0.05, value signiﬁcantly different from baseline value. **Value
signiﬁcantly different using general linear modeling after adjustment for weight loss group.
Table 2—Plasma hs-CRP, adipocytokine, and fetuin-A concentrations before and after inter-
vention in the weight loss and ezetimibe plus weight loss groups
Weight loss Ezetimibe plus weight loss
0 22 weeks 0 22 weeks
n 10 15
hs-CRP (mg/l) 2.2  0.4 2.4  0.5 3.9  1.0 2.2  0.7*†
Interleukin-6 (ng/l) 0.87  0.08 0.91  0.14 1.1  0.1 0.91  0.14*†
Tumor necrosis factor- (ng/l) 5.4  0.5 5.4  0.6 6.3  0.5 5.4  0.6*
Retinol-binding protein-4 (mg/l) 27  16 24  8‡ 27  17 25  20‡
Adiponectin (mg/l) 5.9  0.7 6.8  0.8‡ 4.9  0.7 6.1  0.9*
Fetuin-A (mg/l) 303  31 189  15* 284  24 221  18‡
Data are means  SEM. *P 0.01, value signiﬁcantly different from baseline value. †P  0.05. ‡P 0.05,
value signiﬁcantly different using general linear modeling after adjustment for relative changes in the weight
loss group.
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cholesterol absorption results in reduced
hepatic cholesterol concentrations and,
subsequently,upregulatestheLDLrecep-
tor and enhances LDL–apoB-100 clear-
ance (18). Although we found that
ezetimibe signiﬁcantly reduced choles-
terol absorption, endogenous cholesterol
synthesis increased with ezetimibe treat-
ment, as reﬂected by the increase in
plasma lathosterol concentrations. As
mentioned earlier, it is likely that hepatic
cholesteroldepletionwithezetimibeisac-
companiedbyacompensatoryincreasein
hepaticcholesterolsynthesis.Itisalsoim-
portant to note that the reduction in the
VLDL–apoB-100 secretion rate was nu-
merically smaller in the ezetimibe plus
weight loss group than in the weight loss
group (13 vs. 29%). The increased
cholesterol synthesis with ezetimibe may
blunt the fall in VLDL–apoB-100 secre-
tion with weight loss alone.
Another important ﬁnding from this
study was that addition of ezetimibe to
the weight loss diet further decreased
IHTG content in the setting of similar
changes in body weight, abdominal vis-
ceral and subcutaneous fat areas, and
HOMA score between groups. Although
there has long been speculation that
ezetimibemayreduceIHTGcontent,ours
is the ﬁrst report to show that ezetimibe
reducesIHTGcontentinhumans.Telford
et al. (18) found that hepatic SREBP1c
mRNA was reduced with ezetimibe treat-
ment in miniature pigs. This reduction
could in turn inactivate the hepatic ex-
pressionofgenesinvolvedforlipogenesis.
Inhibition of dietary cholesterol absorp-
tion with ezetimibe may also reduce he-
patic dietary cholesterol availability for
activation of SREBP1c and subsequent li-
pogenesis (19). Evidence supports the
fact that oxidized cholesterol is involved
in hepatic accumulation of triglycerides
(20). Ezetimibe inhibits the intestinal ab-
sorption of oxidized cholesterol (21),
which may be responsible for the reduc-
tion in IHTG. Despite the signiﬁcant ef-
fect of ezetimibe on IHTG, plasma ALT (a
surrogate marker of IHTG) was not al-
tered. Given that the plasma ALT concen-
tration at baseline was on average within
the normal reference range, it is possible
that the plasma ALT concentration was
less sensitive than magnetic resonance
spectroscopy to test between-group dif-
ferences in IHTG. The observed differ-
ences in preintervention IHTG and
abdominal fat content might have con-
founded the results. However, the differ-
ences were not signiﬁcant, and the
preintervention variables had been used
as covariates in general linear modeling,
thereby adjusting for any group
differences.
The present data show that the com-
bined effect of ezetimibe plus weight loss
signiﬁcantly reduced the plasma hs-CRP
concentration compared with weight loss
alone. Previous studies have consistently
shown that ezetimibe reduces plasma hs-
CRP concentrations when given in com-
bination with a statin (22,23). It is
tempting to speculate that similar mech-
anisms of action of ezetimibe are also in-
volved in the setting of moderate weight
loss, although the exact mechanisms by
which ezetimibe reduces hs-CRP are not
fullyunderstood.Consistentwiththereg-
ulatoryroleofIL-6onCRPsynthesis(24),
the signiﬁcant reduction in plasma IL-6
concentrations with ezetimibe in our
studymaythereforepartlyaccountforthe
reduction in plasma hs-CRP concentra-
tions. However, the ﬁnding that the re-
duction in plasma hs-CRP was not
directly associated with a change in IL-6
or IHTG suggests that other factors could
also account for the fall in plasma hs-CRP
with ezetimibe. Previous human studies
have shown that dietary cholesterol is as-
sociated with increased CRP (25). There-
fore, it is possible that decreased
cholesterol absorption with ezetimibe
may also account for the reduction in
plasmahs-CRP.Thisspeculationrequires
further investigation.
The increased cardiovascular mor-
bidity and mortality in human obesity
and type 2 diabetes may be caused by the
combination of insulin resistance, dyslip-
idemia, and inﬂammation. Our data sug-
gest that the combination of ezetimibe
and weight loss reduces plasma LDL cho-
lesterol and apoB-100 concentrations,
two independent predictors of treatment
beneﬁts on cardiovascular outcomes. In
lightofrecentevidencesuggestingtheim-
pact of NAFLD and hs-CRP on CVD, our
new data also indicate that addition of
ezetimibe to weight loss reduces hepatic
steatosis and inﬂammation. Whether this
combined treatment improves clinical
outcomes remains to be fully demon-
strated in clinical trials.
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Table 3—Kinetic indices for apoB-100 before and after intervention in the weight loss and
ezetimibe plus weight loss groups
Weight loss Ezetimibe plus weight loss
0 22 weeks 0 22 weeks
n 10 15
VLDL–apoB-100
Concentration (mg/l) 142  123 123  19† 134  12 109  11†
Fractional catabolic rate
(pools/day) 4.8  1.1 3.8  0.4 3.9  0.4 4.2  0.3
Production rate (mg/kg
FFM/day) 41  52 9  7† 38  33 2  4†
IDL–apoB-100
Concentration (mg/l) 76  10 74  12 82  96 5  9§
Fractional catabolic rate
(pools/day) 3.9  0.7 3.6  0.3 3.5  0.4 4.5  0.5§
Production rate (mg/kg
FFM/day) 20  31 8  22 0  21 8  2
LDL–apoB-100
Concentration (mg/l) 957  61 885  36 952  76 774  62*‡
Fractional catabolic rate
(pools/day) 0.35  0.03 0.34  0.03 0.31  0.02 0.39  0.03*‡
Production rate (mg/kg
FFM/day) 26  32 2  22 2  12 1  2
Data are means  SEM. *P 0.01, value signiﬁcantly different from baseline value. †P  0.05. ‡P 0.05,
value signiﬁcantly different using general linear modeling after adjustment for relative changes in the weight
loss group. §P  0.06, value different from baseline value.
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